Why the study?
Does the combination of interferon alfa-2b and thalidomide improve response rates in patients with metastatic renal cell carcinoma?
Population
30 patients with metastatic renal cell carcinoma (RCC)
Design
Cohort
Authors
Loading...
Modest activity seen in metastatic RCC; leaves open whether combination outperforms interferon alfa-2b alone.
Does the combination of interferon alfa-2b and thalidomide improve response rates in patients with metastatic renal cell carcinoma?
The combination of frequently dosed interferon alfa-2b and low-dose thalidomide is feasible and active in advanced RCC, but clinical benefit may be small compared to interferon alone.
Hernberg et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: